BioMarin Pharmaceutical (NASDAQ:BMRN) announced its earnings results on Thursday. The biotechnology company reported $0.03 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.27) by $0.30, Briefing.com reports. The company had revenue of $358.30 million during the quarter, compared to analyst estimates of $346.59 million. BioMarin Pharmaceutical had a negative net margin of 12.45% and a negative return on equity of 4.60%. The firm’s quarterly revenue was up 19.4% compared to the same quarter last year. During the same period in the previous year, the business posted ($0.16) earnings per share.
BioMarin Pharmaceutical (NASDAQ BMRN) traded down $0.21 on Thursday, hitting $84.00. 1,400,088 shares of the company’s stock were exchanged, compared to its average volume of 1,362,675. The company has a market capitalization of $14,810.00, a price-to-earnings ratio of -101.20 and a beta of 1.71. BioMarin Pharmaceutical has a fifty-two week low of $78.50 and a fifty-two week high of $100.51. The company has a current ratio of 4.91, a quick ratio of 3.81 and a debt-to-equity ratio of 0.41.
In related news, EVP George Eric Davis sold 30,000 shares of the company’s stock in a transaction on Thursday, February 1st. The shares were sold at an average price of $90.66, for a total transaction of $2,719,800.00. Following the completion of the transaction, the executive vice president now owns 112,942 shares in the company, valued at $10,239,321.72. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO Jean Jacques Bienaime sold 10,000 shares of the company’s stock in a transaction on Thursday, February 15th. The stock was sold at an average price of $84.63, for a total transaction of $846,300.00. The disclosure for this sale can be found here. Over the last quarter, insiders sold 100,750 shares of company stock valued at $9,005,888. Company insiders own 1.85% of the company’s stock.
BMRN has been the subject of several recent research reports. JPMorgan Chase & Co. cut their target price on shares of BioMarin Pharmaceutical from $131.00 to $129.00 and set an “outperform” rating for the company in a research report on Wednesday, January 24th. BidaskClub lowered shares of BioMarin Pharmaceutical from a “sell” rating to a “strong sell” rating in a research report on Saturday, January 20th. Zacks Investment Research upgraded shares of BioMarin Pharmaceutical from a “hold” rating to a “buy” rating and set a $101.00 target price for the company in a research report on Tuesday, January 16th. Wedbush restated a “neutral” rating and set a $108.00 target price on shares of BioMarin Pharmaceutical in a research report on Wednesday, November 15th. Finally, BMO Capital Markets boosted their target price on shares of BioMarin Pharmaceutical from $117.00 to $119.00 and gave the company an “outperform” rating in a research report on Friday, October 27th. Two equities research analysts have rated the stock with a sell rating, eight have given a hold rating, fourteen have issued a buy rating and one has given a strong buy rating to the stock. The stock presently has an average rating of “Buy” and an average target price of $111.60.
ILLEGAL ACTIVITY WARNING: This piece was first published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this piece on another domain, it was copied illegally and reposted in violation of United States and international copyright & trademark law. The correct version of this piece can be accessed at https://www.dispatchtribunal.com/2018/02/22/biomarin-pharmaceutical-bmrn-issues-quarterly-earnings-results-beats-expectations-by-0-30-eps.html.
BioMarin Pharmaceutical Company Profile
BioMarin Pharmaceutical Inc is a biotechnology company. The Company develops and commercializes pharmaceuticals for various diseases and medical conditions. As of December 31, 2016, the Company’s therapy portfolio consisted of five products, and multiple clinical and pre-clinical product candidates. Its commercial products include Aldurazyme (laronidase) for Mucopolysaccharidosis I (MPS I), Firdapse (amifampridine phosphate) for Lambert Eaton Myasthenic Syndrome (LEMS), Kuvan (sapropterin dihydrochloride) for phenylketonuria (PKU), Naglazyme (galsulfase) for Mucopolysaccharidosis VI (MPS VI) and Vimizim (elosulfase alpha) for Mucopolysaccharidosis IV Type A (MPS IV A).
Receive News & Ratings for BioMarin Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioMarin Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.